BioCentury
ARTICLE | Clinical News

BMS-955176: Additional Phase IIa data

November 9, 2015 8:00 AM UTC

Data from 60 patients with HIV-1 subtype B in the open-label Part A portion of the international Phase IIa AI468002 trial showed that once-daily oral BMS-955176 reduced median HIV-1 RNA levels from baseline to day 11 by 0.15 log10 copies/mL at the 5 mg dose, 0.74 log10 copies/mL at the 10 mg dose, 0.82 log10 copies/mL at the 20 mg dose, 1.21 log10 copies/mL at the 40 mg dose, 1.35 log10 copies/mL at the 80 mg dose and 1.36 log10 copies/mL at the 120 mg dose vs. 0.03 log10 copies/mL for placebo. The maximum median reduction in plasma HIV-1 RNA levels was 0.5 log10 copies/mL at the 5 mg dose, 0.98 log10 copies/mL at the 10 mg dose, 1.12 log10 copies/mL at the 20 mg dose, 1.7 log10 copies/mL at the 40 mg dose, 1.56 log10 copies/mL at the 80 mg dose and 1.65 log10 copies/mL at the 120 mg dose vs. 0.38 log10 copies/mL for placebo. ...